Clinical Trials Directory

Trials / Completed

CompletedNCT00004328

Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
1 (planned)
Sponsor
National Center for Research Resources (NCRR) · NIH
Sex
All
Age
0 Years
Healthy volunteers
Not accepted

Summary

OBJECTIVES: I. Establish the sodium and potassium intake that will maintain a normovolemic state in a patient with pseudohypoaldosteronism. II. Determine the effect of extracellular fluid volume and serum potassium manipulations on exercise tolerance, cardiac function, and endurance. III. Investigate pharmacologic methods of limiting excretion of sodium in urine and sweat.

Detailed description

PROTOCOL OUTLINE: Sodium and potassium intake resulting in normalization of serum electrolytes and markers of extracellular volume are determined at baseline. A trial diet is then prescribed, with adjustments made to achieve a steady state with normal serum electrolytes. Exercise tolerance and muscle function are evaluated at steady state. Sodium and potassium are sequentially manipulated with diet, enalapril, and polystyrene sulfonate. Exercise tolerance is evaluated during each diet period. A treatment plan to maintain electrolyte balance is developed. The patient is followed monthly for 3 to 6 months, then every 3 months for up to 3 years.

Conditions

Interventions

TypeNameDescription
DRUGenalapril
DRUGpolystyrene sulfonate

Timeline

Start date
1992-12-01
First posted
1999-10-19
Last updated
2005-06-24

Source: ClinicalTrials.gov record NCT00004328. Inclusion in this directory is not an endorsement.

Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism (NCT00004328) · Clinical Trials Directory